OKYO
OKYO Pharma Limited · Healthcare
Insiders bought $96K of OKYO Pharma Limited in the last 12 months
2 insiders bought on 2 days.
OKYO over the last year
Largest buyers, last 12 months
OKYO after insider buys
3 months after each buy, from the first price a copier could get.
1 buy has 3 months of prices so far. A record shows here at 3.
Every filing
4 insider filings since 2023, newest first
About OKYO Pharma Limited
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.